scispace - formally typeset
P

Patrick J. Lillie

Researcher at University of Hull

Publications -  73
Citations -  8039

Patrick J. Lillie is an academic researcher from University of Hull. The author has contributed to research in topics: Medicine & Biology. The author has an hindex of 18, co-authored 50 publications receiving 4164 citations. Previous affiliations of Patrick J. Lillie include Royal Hallamshire Hospital & Hull and East Yorkshire Hospitals NHS Trust.

Papers
More filters
Journal ArticleDOI

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

Merryn Voysey, +81 more
- 09 Jan 2021 - 
TL;DR: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.
Journal ArticleDOI

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.

Merryn Voysey, +766 more
- 06 Mar 2021 - 
TL;DR: The ChAdOx1 nCoV-19 (AZD1222) vaccine has been approved for emergency use by the UK regulatory authority, Medicines and Healthcare products Regulatory Agency, with a regimen of two standard doses given with an interval of 4-12 weeks as discussed by the authors.
Journal ArticleDOI

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial.

Katherine R. W. Emary, +69 more
- 10 Apr 2021 - 
TL;DR: A post-hoc analysis of the efficacy of the adenoviral vector vaccine, ChAdOx1 nCoV-19 (AZD1222), against B.1.7, emerged as the dominant cause of COVID-19 disease in the UK from November, 2020 as discussed by the authors.
Journal ArticleDOI

Potent CD8+ T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA−NP+M1

TL;DR: The vaccine was generally safe and well tolerated, with significantly fewer local side effects after intramuscular rather than intradermal administration, and frequencies of responding T cells that appear to be much higher than those induced by any other influenza vaccination approach.